Role and mechanism of Roux-en-Y gastric bypass in the treatment of diabetic urinary bladder hyperactivity by reducing TRPV1 and P2X3

Figure 1 Body weight and blood glucose of mice after Roux-en-Y gastric bypass treatment. A: Body weights of mice before and after treatment; B and D: Changes in oral glucose tolerance test (OGTT) values and area under the glucose curve (AUC); C and E: Changes in insulin tolerance test (ITT) values and AUC. All statistical results were expressed as mean ± SD (n = 8). ^aP < 0.05, overactive bladder (OAB) compared with the sham group; ^bP < 0.05, Roux-en-Y gastric bypass (RYGB) compared with the OAB group.